COVA322是一种双特异性 TNF 和 IL-17A 抗体。COVA322可同时抑制 TNF 和 IL-17A 同型二聚体，可用于研究炎症疾病。

For Powder, reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. Gently shake to solubilize completely. Do not vortex.

本产品仅用作科学研究！

The detected molecular weight of Anti-IL-17 & TNF-alpha Reference Antibody (COVA322) is 161.78 kDa.

Anti-IL-17 & TNF-alpha Reference Antibody (COVA322) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

The purity of Anti-IL-17 & TNF-alpha Reference Antibody (COVA322) is 98.28%, determined by SEC-HPLC.

Cova322 bound to CTLA-8 / IL-17a protein, and then rebounded to secondary antibodies(Anti-Human-IgG-Fc-HRP) , and read OD450. As shown in fig, Cova322 bound human CTLA-8 / IL-17a Protein-His, and the EC50 was 0.03639 nM.

Cova322 bound to TNFSF2 / TNFα protein, and then rebounded to secondary antibodies(Anti-Human-κ+λ-HRP) , and read OD450. As shown in fig, Cova322 bound TNFSF2 / TNFa, and the EC50 was 0.03458 nM.

Cova322 bound to HuTNF-a-his/CHO-K(0706-32-15) cells, and then rebounded to fluorescent secondary antibodies(Anti-Human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Cova322 bound to HuTNF-a-his/CHO-K(0706-32-15) cells, and the EC50 was 99.590 nM.

-80°C for 2 years under sterile conditions；-20°C for 1 year under sterile conditions；Avoid repeated freeze-thaw cycles.